Join IQVIA Biotech at booth #33 during the Clinical Outsourcing Group (COG) New England meeting on April 23-24, 2024 hosted at the Boston Marriott. COG New England unites senior decision-makers from across New England and the broader East Coast to engage with industry thought leaders, regulators, academicians and innovative solution providers, like IQVIA Biotech, together to lead a curated agenda and networking opportunity.
While at COG NE, be sure to attend “The Next Frontier in Early Phase Oncology Trials” on April 23rd, presented by Erin Finot, Vice President, Immuno-Oncology and Cell and Gene Therapy, IQVIA Biotech. Erin will share insights into optimizing study protocols and enhancing clinical trial diversity while adhering to regulatory compliance.
SESSION DETAILS
Title: The Next Frontier in Early Phase Oncology Trials
Description: First-in-Human and early phase oncology trials serve as the launch point in a company’s pursuit for drug development as they offer an early glimpse into the safety profile of a novel investigational product. Dynamic by nature, these trials necessitate holistic planning to ensure successful implementation and delivery.
In this session, sponsors will explore:
- Optimizing Study Protocols: Discover tools to streamline study protocols, alleviating patient burden and minimizing the need for future amendments.
- Project Optimus Impact: Understand how Project Optimus influences early phase oncology operations.
- Diversity and Compliance: Explore strategies to enhance clinical trial diversity while adhering to the FDA’s DEPICT Act.